Unicycive End Period Cash Flow from 2010 to 2024

UNCY Stock  USD 0.55  0.02  3.77%   
Unicycive Therapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow will likely drop to about 4.9 M in 2024. During the period from 2010 to 2024, Unicycive Therapeutics End Period Cash Flow regression line of annual values had r-squared of  0.29 and arithmetic mean of  2,137,180. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
9.7 M
Current Value
4.9 M
Quarterly Volatility
4.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 77.9 K, Net Interest Income of 429.4 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Unicycive Therapeutics Correlation against competitors.
For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Latest Unicycive Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Unicycive Therapeutics over the last few years. It is Unicycive Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Unicycive End Period Cash Flow Regression Statistics

Arithmetic Mean2,137,180
Geometric Mean107,690
Coefficient Of Variation225.46
Mean Deviation3,307,221
Median25,000
Standard Deviation4,818,530
Sample Variance23.2T
Range16.6M
R-Value0.53
Mean Square Error17.9T
R-Squared0.29
Significance0.04
Slope575,510
Total Sum of Squares325.1T

Unicycive End Period Cash Flow History

20244.9 M
20239.7 M
2022455 K
202116.6 M
2020147 K
201915 K

About Unicycive Therapeutics Financial Statements

Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow9.7 M4.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.